Univariate Analyses Treatment Outcome And Patterns Of Relapse Following Adjuvant Carboplatin For Stage I Testicular Seminoma: Results From a 17 Year UK.

Slides:



Advertisements
Similar presentations
Yasir Rudha, MD; Amr Aref, MD; Paul Chuba, MD; Kevin O’Brien, MD
Advertisements

Advances and Emerging Therapy for Lung Cancer
Management Strategies for Stage I germ cell tumours
How to Manage High Risk Myeloma Dr Matthew Jenner Consultant Haematologist Southampton General Hospital UK Myeloma Forum Autumn Day 12 November 2014.
Testicular Tumours Part 2
Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.
H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.
Casulo C et al. Proc ASH 2013;Abstract 510.
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
Giuliano Pre-SSO mins ASCO Z mins
PREOPERATIVE PLASMA CONCENTRATION OF MMP-9/TIMP-1 COMPLEXES IS NOT ASSOCIATED WITH DISEASE OUTCOME IN PRIMARY BREAST CANCER (N=483) Anne-Sofie Schrohl.
Testicular cancer: current views Dr. M. Mangala MD (Kin); FRCS (Ireland); MMed (Wits); FCS (SA) Urology 38 th BMA CONGRESS.
Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.
Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group.
Hot topics in breast radiotherapy Mark Beresford.
The All Breast Cancer Report was published in October breastscreen/research.html#breast- cancer-report.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Dr. Kenneth Lim Urology – MSU-COM POH McLaren Medical Center
Se cond Cancers and Residual Disease in Patients Treated for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma by Helicobacter pylori Eradication and.
Utility of Post-Therapy Surveillance Scans in Diffuse Large B-Cell Lymphoma Thompson C et al. Proc ASCO 2013;Abstract 8504.
Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.
Results of an Ontario Clinical Oncology Group (OCOG) prospective cohort study on the use of FDG PET/CT to predict the need for.
Resection For Lung Metastases M62 Coloproctology Course.
Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.
National Oesophago–Gastric Cancer Audit Key Findings from 2014 Annual Report and Progress Report Georgina Chadwick Clinical Research Fellow.
Dr Poonam Valand, Foundation Year Two Dr Anjan Dhar, Consultant Gastroenterologist COUNTY DURHAM AND DARLINGTON NHS FOUNDATION TRUST Early gastric cancer.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Are there benefits from chemotherapy to early endometrial cancer
SPINDLE CELL SARCOMA OF BONE AN ASSESSMENT OF OUTCOME
State of the Art: Gestational Trophoblastic Lesions Treatment beyond single agents Barry Hancock (Sheffield, UK) International Gynecologic Society Meeting.
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can.
Involved Field Radiotherapy versus No Further Treatment in Patients with Clinical Stages IA/IIA Hodgkin Lymphoma and a “Negative” PET Scan After 3 Cycles.
Ten Year Outcomes In Men Under 60 Treated With Iodine-125 Permanent Brachytherapy As Monotherapy GU - Prostate Cancer: Novel Imaging (MRI,PET) & Brachytherapy.
SYNCHRONOUS COLORECTAL AND LIVER RESECTION J Peter A Lodge MD FRCS HPB and Transplant Unit St James’s University Hospital Leeds LS9 7TF 2006 Association.
Testicular Cancer Part 1
Tumours of the testis 1. Introduction ❏ any solid testicular mass in young patient – must rule out malignancy ❏ slightly more common in right testis (corresponds.
Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomized trial Authors: Oliver et al,
A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of newly diagnosed diffuse large B cell lymphoma Results from a UK NCRI Lymphoma.
Neil Rabin Consultant Haematologist on behalf of Dr Nicola Maciocia
The Royal Marsden Solitary fibrous tumours The outcomes of 106 patients illustrating the unpredictable biological behaviour N Alexander, K Thway, JM Thomas,
Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Mitsui Memorial Hospital Department of Breast and.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,
Carboplatin Not Inferior to Radiation as Adjuvant Therapy for Stage I Seminoma Slideset on: Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose.
What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.
Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.
Patterns of care and comparative effectiveness of endocrine therapy for premenopausal women with early breast cancer A multi-institution cohort study February.
Bladder Cancer R. Zenhäusern.
Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.
Brain imaging prior to lung cancer resection
Prognostic significance of tumor subtypes in male breast cancer:
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.
1 Maidstone and Tunbridge Wells NHS Trust (Kent Oncology Centre)
Brain imaging prior to lung cancer resection
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Director Department of Pediatric Hematology & Oncology Delhi, INDIA.
Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.
DENİZ KAVGACI HALİME HELİN YILMAZ
Dr Jessica Jenkins Consultant Oncologist
Dr T P E Wells 13 July 2018 Breast SSG Bath
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
Published online Feb 7, 2019 Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling:
Penile and Testicular Cancer: What's New in 2006?
Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &
Presentation transcript:

Univariate Analyses Treatment Outcome And Patterns Of Relapse Following Adjuvant Carboplatin For Stage I Testicular Seminoma: Results From a 17 Year UK Experience Caroline Chau 1,2,3, Matthew Wheater 3, Richard Cathomas 4, Martin Fehr 5, James Bennett 6,Dirk Klingbiel 7, Hannah Markham 3, Chern Lee 1,3,Simon J. Crabb 1,3, Thomas Geldart 6 1. Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK 2. NIHR Wellcome Trust Clinical Research Facility, University of Southampton, Southampton, UK 3. Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK 4. Medical Oncology, Kantonsspital Graubünden, Chur, Switzerland 5. Medical Oncology, Kantonsspital St. Gallen Hospital, St. Gallen, Switzerland 6. Dorset Cancer Centre, Poole Hospital NHS Foundation Trust, Poole, UK 7. Swiss Group for Clinical Cancer Research Coordinating Center Background Conclusions This is the first non-trial series describing the clinical outcome and relapse pattern of patients with stage I seminoma treated with a single cycle of adjuvant carboplatin chemotherapy (AUC 7) dosed using radioisotope measured GFR Our data confirms that routine clinical practice for these patients within the context of a high volume centre is comparable in outcome to prospective trial data Relapse beyond 3 years was rare (0.8%) Tumour size greater than 40mm was associated with a higher rate of relapse Salvage treatment at relapse Aim and Method Patient Characteristics 518 consecutive patients identified Median age at diagnosis 38 years (range 18 – 73). Median follow up was 47.2 months (range 0.4 – 217) 5-year cancer-specific survival is 100% (6 patients died, all deaths unrelated to seminoma) Patterns of relapse Stage I seminoma: The commonest presentation of testicular germ cell tumours (GCT) with excellent prognosis Approximately 80% of patients are cured with orchidectomy alone No prospectively defined risk categories - retrospective series showed tumour size >40mm and rete testis invasion had a significantly higher relapse rate of up to 32% (Warde P et al; JCO 2002) Salvage therapy at relapse is highly effective irrespective of post- ochidectomy strategy Active surveillance (relapse rate of 15 – 20%) Detect relapse early whilst avoiding morbidities and risks of adjuvant treatment Need for intensive follow up and patient compliance is paramount No consensus regarding the optimum surveillance schedule Adjuvant therapy (relapse rate of 4 – 5%) Adjuvant radiotherapy (ART) vs. adjuvant chemotherapy (ACT) TE-19 trial showed non-inferiority of ACT with a single dose of carboplatin (AUC7) compared with ART (RFR at 5 years of 94.7% and 96.0% respectively) (Oliver RT et al, JCO 2005/2011) Carboplatin treated patients were less lethargic and less likely to take time off work after treatment and developed fewer contralateral GCT Aim To provide real world data of clinical outcome and patterns of relapse in patients with stage I seminoma treated with a single dose of adjuvant carboplatin chemotherapy (AUC 7) All patients underwent radioisotope measurement of GFR Method A retrospective study including patients from 3 cancer centres (Southampton, Portsmouth, Dorset) between July 1996 to October 2013 Tumour size ≤40 mm >40mm Unknown 333 (64.3%) 169 (32.6%) 16 (3.1%) Rete testis invasion No Yes Unknown 331 (63.9%) 166 (32.0%) 21 (4.1%) >40mm and rete testis invasion No Yes Unknown 427 (82.4%) 65 (12.5%) 26 (5.0%) Time to adjuvant carboplatin (days) ≤ >60 Unknown 103 (19.9%) 284 (54.8%) 112 (21.6%) 19 (3.7%) No. of relapse Relapse rate 5-year RFS p value Tumour size ≤40 mm >40 mm Unknown 11/333 10/169 1/16 3.3% 5.9% 6.3% 95.5% 93.6% 0.05 Rete testis invasion No Yes Unknown 13/331 7/166 2/21 3.9% 2.2% 9.5% 95.1% 94.9% 0.75 >40 mm & rete invasion No Yes Unknown 17/427 3/65 2/19 4.0% 4.6% 7.7% 95.1% 94.0% 0.67 Time to adjuvant carboplatin ≤30 days 31 – 60 days >60 days Unknown 4/103 14/284 3/112 1/19 3.9% 4.9% 2.7% 5.3% 95.4% 93.9% 96.4% Univariate analyses for possible risk factors for relapse 22 patients relapsed (4.2%) Estimated relapse free survival (RFS) 97.3% at 2 years (95% CI 95.8 – 98.7%) 94.8% at 5 years (95% CI 92.6 – 97.1%) Median time to relapse was 22.4 months (range 11 – 108) 82% of relapsing patients did so within the first 3 years. 4 patients (0.8%) relapsed after 3 years (at 49, 50, 53, 108 months) Setting of relapse detection Detected at routine follow up Unplanned 14 (64%) 8 (36%) First indicator of relapse Abdominal CT Elevated tumour markers Other abdominal imaging 16 (72%) 3 (14%) Elevated LDH or β-HCG at relapse Yes No Unknown 17 (77%) 4 (18%) 1 (5%) Site of relapse Retroperitoneal lymph nodes Iliac lymph nodes Multiple nodal sites Multiple nodal + visceral 18 (82%) 1 (4.5%) 2 (9%) 1 (4.5%) IGCCCG risk group at relapse Good prognosis Intermediate prognosis 21 (95%) 1 (5%) Salvage therapy at 1 st relapse Chemotherapy Dogleg radiotherapy 18 (82%) 4 (18%) Salvage chemotherapy regime at 1 st relapse BEP x 3 Modified BEP x 4 BEP x 4 Other 8 (44%) 6 (33%) 1 (6%) 3 (17%) 22 patients relapsed Second relapse 3 cisplatin containing chemotherapy (TIP, EP) 1 radiotherapy Third relapse 1 x4 TIP chemotherapy 18 salvage chemotherapy 4 salvage radiotherapy First relapse 18 alive and disease free 2 alive and disease free 1 dead 1 alive and disease free 518 patients Corresponding author: Dr. Caroline Chau